James Smithy is an Oncology physician affiliated with Memorial Sloan Kettering Cancer Center. OpenAlex indexes 95 publications with 1,537 citations (h-index 15); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
160 E 53rd St
New York, NY 100225243
Telephone
212-639-2000Provider last certified this registry record 30 Apr 2023.
Clinical trials
- A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
Sponsor: Memorial Sloan Kettering Cancer Center
- A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
Sponsor: Memorial Sloan Kettering Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Daiichi Sankyo Inc.Program year20251 payment
- E.R. Squibb & Sons, L.L.C.Program year20251 payment
- Iovance Biotherapeutics, Inc.Program year20247 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
62.2%Kinase inhibitor36.4%Tafinlar56%Mekinist44%Part D<11 patientsB-Raf serine-threonine kinase (BRAF) inhibitors12.9%Braftovi100%Part D<11 patients+ 1 more class in this area
Hormonal (systemic)
12.9%l-Thyroxine12.9%Levothyroxine Sodium100%Part D<11 patientsMetabolism & gastrointestinal
12.9%Corticosteroid12.9%Prednisone100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The Clinical TIL Experience in Melanoma: Past, Present, Future
Biology of Blood and Marrow Transplantation
2025 - Malignant <scp>CRTC1</scp>::<scp>TRIM11</scp> Cutaneous Tumor With Lethal Outcome: Histopathologic and Molecular Findings
Journal of Cutaneous Pathology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Valerie Rusch, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”